article Open AccessTop 1% cited

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

New England Journal of Medicine · 2016 · Vol. 375(19) · pp. 1823–1833

Martin Reck✉(LungenClinic Grosshansdorf)Delvys Rodríguez‐Abreu(LungenClinic Grosshansdorf)Andrew Robinson(LungenClinic Grosshansdorf)Rina Hui(Westmead Hospital)Tibor Csőszi(LungenClinic Grosshansdorf)Andrea Fülöp(LungenClinic Grosshansdorf)Maya Gottfried(LungenClinic Grosshansdorf)Nir Peled(Rabin Medical Center)Ali Tafreshi(LungenClinic Grosshansdorf)Sinéad Cuffe(Cancer Trials Ireland)Mary O’Brien(Royal Marsden Hospital)Suman Rao(LungenClinic Grosshansdorf)Katsuyuki Hotta(Okayama University Hospital)Melanie A. Leiby(Merck & Co., Inc., Rahway, NJ, USA (United States))Gregory M. Lubiniecki(Merck & Co., Inc., Rahway, NJ, USA (United States))Yue Shentu(LungenClinic Grosshansdorf)Reshma Rangwala(Merck & Co., Inc., Rahway, NJ, USA (United States))Julie R. Brahmer(LungenClinic Grosshansdorf)

View via DOI Full-text PDF

Abstract

In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and TreatmentPembrolizumabMedicineLung cancerInternal medicineHazard ratioOncologyChemotherapyCancerGastroenterologyConfidence interval

MeSH terms

AdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedSurvival AnalysisPlatinum CompoundsIntention to Treat AnalysisProgrammed Cell Death 1 Receptor

Citations

9,911

FWCI

482.10

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Distal femur endoprosthesis for pathological femur fractures: A multidisciplinary approach to management